• Cy5 Azide: Identity and Evidence Scope

  2026-10-19

  Cy5 azide (non-sulfonated), SKU A8113, is a supplier-described azide-bearing Cy5 fluorescent labeling reagent for conceptual use with alkyne-modified biomolecules. The available evidence supports its chemical identity, optical specifications, and solubility profile, but not independent performance claims or biological conclusions.

• DiscoveryProbe Library: Scope and Evidence

  2026-10-19

  The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is described by APExBIO as a 2,320-compound collection of clinically approved or pharmacopeial bioactive molecules supplied in DMSO for research screening. Its principal scientific value is breadth across pharmacological classes, not a single shared mechanism. The available product description supports an identity and scope overview, but provides no identity-matched study, assay results, effect sizes, target-validation data, or evidence for disease-specific performance.

• Urotensin II (114–124): Evidence Scope

  2026-10-18

  The APExBIO listing identifies Urotensin II (114–124, human) TFA as a named peptide material, but provides no identity-matched research evidence, mechanistic description, measurement context, or performance data. The defensible interpretation is therefore limited to product nomenclature and clearly stated evidence boundaries.

• β-Galactosidase Reporter Assay Kit: Evidence Scope

  2026-10-17

  The product page identifies APExBIO’s K2183 as a β-galactosidase reporter assay kit, but provides no substantive description of its substrate, detection modality, formulation, validation data, or intended model system. The available evidence therefore supports only a cautious, conceptual account of reporter-assay identity and measurement interpretation—not claims about product performance or documented experimental outcomes.

• Sulfo-Cy7 NHS Ester: Evidence and Scope

  2026-10-16

  A source-grounded overview of Cy7 NHS ester (A8109) as a sulfonated near-infrared dye for conceptual amino-group labeling. The supplier description supports its chemical identity, reported optical properties, and intended measurement context, but no identity-matched research paper was available to establish labeling performance, biological behavior, or comparative imaging outcomes.

• Abacavir Sulfate: Evidence and Scope

  2026-10-16

  A source-bounded overview of Abacavir sulfate (ABC), separating APExBIO’s documented product identity and vendor-stated reverse-transcriptase mechanism from evidence that would require an identity-matched research study.

• 2X HyperFusion: Claims and Evidence Boundaries

  2026-10-15

  APExBIO describes the 2X HyperFusion™ High-Fidelity Master Mix as a premixed PCR formulation containing a fusion-based proofreading polymerase. Its stated mechanism is consistent with higher-fidelity amplification and blunt-ended products, but no identity-matched research paper is available here to independently verify the reported error-rate, fragment-length, or reproducibility claims.

• SNS-032 (BMS-387032): Evidence and Scope

  2026-10-15

  APExBIO describes SNS-032 (BMS-387032) as a small-molecule inhibitor of CDK2, CDK7, and CDK9, with downstream effects on RNA polymerase II C-terminal-domain phosphorylation. The available material reports biochemical potency, observations in chronic lymphocytic leukemia cells, and a breast cancer xenograft result, but provides no identity-matched paper, study-level comparators, sample sizes, or uncertainty estimates.

• When Context Changes What a Cdc42 Result Means

  2026-10-14

  The same Cdc42-linked observation can signify pathway engagement, cytoskeletal disruption, stress protection, or reduced fibrosis depending on the model and readout. Evidence involving ZCL278 helps interpret the daphnepedunin A kidney-fibrosis study, but it does not make results from neuronal, cancer, or supplier-reported assays interchangeable.

• Cell Integrity and the Limits of Yeast Ploidy

  2026-10-14

  Barker, Murray, and Bell report that budding yeast reached a DNA-content range of roughly 32–64C after repeated genome replication, while physical factors affecting cell-surface stress shifted that upper limit. The study supports a model in which genome expansion, cell growth, and surface integrity are coupled, but it does not test Amorolfine Hydrochloride, antifungal treatment, or clinical fungal infection.

• Silymarin: Chemistry, Evidence, and Limits

  2026-10-13

  The supplied evidence supports a chemistry-centered interpretation of Silymarin and cautions against treating a heterogeneous milk thistle extract as equivalent to purified silybin or as proof of clinical efficacy.

• PTGER4–HDAC Signaling in Rectal Epithelium

  2026-10-13

  Anbazhagan et al. report that MSC-associated PGE2 signaling through PTGER4 is linked to class IIa HDAC phosphorylation and increased SPINK4 expression in rectal epithelial organoids. The findings support a mechanistic model, but the evidence remains primarily ex vivo and pharmacological rather than proof of in vivo causation or therapeutic benefit.

• SIRT1, Bone Aging, and EX 527 Evidence

  2026-10-12

  A source-grounded overview of SIRT1 in vascular–osteogenic bone repair, the reported role of β-catenin signaling, and the interpretive scope of EX 527 (SEN0014196) as a selective SIRT1 catalytic-activity inhibitor.

• AZD8055: Documented Identity and Evidence Scope

  2026-10-12

  AZD8055 is listed by APExBIO as a selective ATP-competitive mTOR inhibitor intended as a research tool for conceptual study of mTORC1 and mTORC2 signaling. The available evidence here is limited to a supplier description, so its reported potency, selectivity, preclinical activity, and clinical history cannot be independently assessed.

• Losmapimod and p38α Dephosphorylation

  2026-10-11

  A source-grounded overview of a 2024 bioRxiv preprint examining how kinase-inhibitor binding changes p38α activation-loop conformation and WIP1-mediated dephosphorylation. The findings support a preliminary mechanistic model, but the supplied evidence does not establish that Losmapimod or GW856553X was tested, nor that the mechanism operates in cells or patients.

8215 records 1/548 page Next 12345 下5页 Last page